1. Home
  2. PGEN vs GUG Comparison

PGEN vs GUG Comparison

Compare PGEN & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • GUG
  • Stock Information
  • Founded
  • PGEN 1998
  • GUG 2021
  • Country
  • PGEN United States
  • GUG United States
  • Employees
  • PGEN N/A
  • GUG N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • GUG Trusts Except Educational Religious and Charitable
  • Sector
  • PGEN Health Care
  • GUG Finance
  • Exchange
  • PGEN Nasdaq
  • GUG Nasdaq
  • Market Cap
  • PGEN 448.7M
  • GUG 470.0M
  • IPO Year
  • PGEN N/A
  • GUG N/A
  • Fundamental
  • Price
  • PGEN $1.67
  • GUG $15.26
  • Analyst Decision
  • PGEN Strong Buy
  • GUG
  • Analyst Count
  • PGEN 3
  • GUG 0
  • Target Price
  • PGEN $6.00
  • GUG N/A
  • AVG Volume (30 Days)
  • PGEN 3.0M
  • GUG 108.9K
  • Earning Date
  • PGEN 08-13-2025
  • GUG 01-01-0001
  • Dividend Yield
  • PGEN N/A
  • GUG 9.67%
  • EPS Growth
  • PGEN N/A
  • GUG N/A
  • EPS
  • PGEN N/A
  • GUG N/A
  • Revenue
  • PGEN $4,201,000.00
  • GUG N/A
  • Revenue This Year
  • PGEN $256.94
  • GUG N/A
  • Revenue Next Year
  • PGEN $759.81
  • GUG N/A
  • P/E Ratio
  • PGEN N/A
  • GUG N/A
  • Revenue Growth
  • PGEN N/A
  • GUG N/A
  • 52 Week Low
  • PGEN $0.65
  • GUG $12.71
  • 52 Week High
  • PGEN $2.17
  • GUG $15.06
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 51.21
  • GUG 41.65
  • Support Level
  • PGEN $1.54
  • GUG $15.26
  • Resistance Level
  • PGEN $1.85
  • GUG $15.49
  • Average True Range (ATR)
  • PGEN 0.14
  • GUG 0.22
  • MACD
  • PGEN -0.02
  • GUG -0.01
  • Stochastic Oscillator
  • PGEN 40.00
  • GUG 16.89

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

Share on Social Networks: